10/28/2010

The FDA has cited problems at Bristol-Myers Squibb's Puerto Rico plant, a facility that the company wants to use for packaging biologic drug belatacept, and the agency said it won't approve the drug until corrections are made and contamination-prevention procedures are in place.

Related Summaries